PROTEOMICS,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Nov. 11, 2024
Omics
technologies
have
significantly
advanced
the
prediction
and
therapeutic
approaches
for
chronic
kidney
disease
(CKD)
by
providing
comprehensive
molecular
insights.
This
is
a
review
of
current
state
future
prospects
integrating
biomarkers
into
clinical
practice
CKD,
aiming
to
improve
patient
outcomes
targeted
interventions.
In
fact,
integration
genomic,
transcriptomic,
proteomic,
metabolomic
data
has
enhanced
our
understanding
CKD
pathogenesis
identified
novel
an
early
diagnosis
treatment.
Advanced
computational
methods
artificial
intelligence
(AI)
further
refined
multi-omics
analysis,
leading
more
accurate
models
progression
responses.
These
developments
highlight
potential
care
with
precise
individualized
treatment
plan
.
Journal of Clinical Investigation,
Journal Year:
2023,
Volume and Issue:
133(20)
Published: Aug. 24, 2023
Diabetic
kidney
disease
(DKD)
can
lead
to
end-stage
(ESKD)
and
mortality;
however,
few
mechanistic
biomarkers
are
available
for
high-risk
patients,
especially
those
without
macroalbuminuria.
Urine
from
participants
with
diabetes
the
Chronic
Renal
Insufficiency
Cohort
(CRIC)
study,
Singapore
Study
of
Macro-angiopathy
Micro-vascular
Reactivity
in
Type
2
Diabetes
(SMART2D),
American
Indian
determined
whether
urine
adenine/creatinine
ratio
(UAdCR)
could
be
a
biomarker
ESKD.
ESKD
mortality
were
associated
highest
UAdCR
tertile
CRIC
study
SMART2D.
was
patients
macroalbuminuria
SMART2D,
study.
Empagliflozin
lowered
nonmacroalbuminuric
participants.
Spatial
metabolomics
localized
adenine
pathology,
single-cell
transcriptomics
identified
ribonucleoprotein
biogenesis
as
top
pathway
proximal
tubules
macroalbuminuria,
implicating
mTOR.
Adenine
stimulated
matrix
tubular
cells
via
mTOR
mouse
kidneys.
A
specific
inhibitor
production
found
reduce
hypertrophy
injury
diabetic
mice.
We
propose
that
endogenous
may
causative
factor
DKD.
Molecules,
Journal Year:
2024,
Volume and Issue:
29(10), P. 2198 - 2198
Published: May 8, 2024
As
links
between
genotype
and
phenotype,
small-molecule
metabolites
are
attractive
biomarkers
for
disease
diagnosis,
prognosis,
classification,
drug
screening
treatment,
insight
into
understanding
pathology
identifying
potential
targets.
Metabolomics
technology
is
crucial
discovering
targets
of
involved
in
phenotype.
Mass
spectrometry-based
metabolomics
has
implemented
applications
various
fields
including
target
discovery,
explanation
mechanisms
compound
screening.
It
used
to
analyze
the
physiological
or
pathological
states
organism
by
investigating
changes
endogenous
associated
metabolism
from
complex
metabolic
pathways
biological
samples.
The
present
review
provides
a
critical
update
high-throughput
functional
techniques
diverse
applications,
recommends
use
mass
metabolite
signatures
that
provide
valuable
insights
We
also
recommend
using
as
powerful
tool
patterns,
efficacy
evaluation
herbal
medicine.
American Journal of Nephrology,
Journal Year:
2024,
Volume and Issue:
55(4), P. 421 - 438
Published: Jan. 1, 2024
<b><i>Background:</i></b>
Chronic
kidney
disease
(CKD)
presents
a
persistent
global
health
challenge,
characterized
by
complex
pathophysiology
and
diverse
progression
patterns.
Metabolomics
has
emerged
as
valuable
tool
in
unraveling
the
intricate
molecular
mechanisms
driving
CKD
progression.
<b><i>Summary:</i></b>
This
comprehensive
review
provides
summary
of
recent
progress
field
metabolomics
with
focus
on
spatial
to
shed
important
insights
enhancing
our
understanding
progression,
emphasizing
its
transformative
potential
early
detection,
refined
risk
assessment,
development
targeted
interventions
improve
patient
outcomes.
<b><i>Key
Message:</i></b>
Through
an
extensive
analysis
metabolic
pathways
small-molecule
fluctuations,
bulk
offers
unique
spanning
entire
spectrum
CKD,
from
stages
advanced
states.
Recent
advances
technology
have
enabled
identification
biomarkers
provide
breakthrough
discoveries
predicting
trajectory
enabling
personalized
assessment.
Furthermore,
can
help
decipher
intricacies
associated
diseases
for
exciting
novel
therapeutic
approaches.
A
example
is
adenine
key
marker
fibrosis
diabetic
using
both
untargeted
metabolomics.
The
studies
were
critical
identify
new
biomarker
failure
guide
therapeutics
disease.
Similar
approaches
are
being
pursued
acute
injury
other
enhance
precision
medicine
decision-making.
Metabolites,
Journal Year:
2024,
Volume and Issue:
14(9), P. 474 - 474
Published: Aug. 28, 2024
Discrepant
sample
processing
remains
a
significant
challenge
within
blood
metabolomics
research,
introducing
non-biological
variation
into
the
measured
metabolome
and
biasing
downstream
results.
Inconsistency
during
pre-analytical
phase
can
influence
experimental
processes,
producing
measurements
that
are
non-representative
of
in
vivo
composition.
To
minimize
variation,
there
is
need
to
create
adhere
standardized
protocols
for
samples
intended
use
analyses.
This
will
allow
reliable
reproducible
findings
research.
In
this
review
article,
we
provide
an
overview
existing
literature
pertaining
factors
metabolite
measurements.
Pre-analytical
including
tube
selection,
pre-
post-processing
time
temperature
conditions,
centrifugation
freeze-thaw
cycles,
long-term
storage
conditions
specifically
discussed,
with
recommendations
provided
best
practices
at
each
stage.
TrAC Trends in Analytical Chemistry,
Journal Year:
2023,
Volume and Issue:
168, P. 117287 - 117287
Published: Sept. 17, 2023
Biofluid
metabolomics
is
a
popular
tool
for
biomarker
discovery
to
decipher
disease-,
genetics-,
and
exposure-related
metabolic
alterations
an
essential
component
understanding
integrated
metabolite-level
responses.
The
conventional
workflow
in
mass
spectrometry
(MS)
involves
hyphenation
with
chromatographic
separation
represents
valuable
analytical
both
research
clinical
settings.
However,
complexity,
relatively
low
throughput,
high
costs
often
hinder
implementation
when
routine,
large-scale
analysis
sample
turnover
desired,
such
as
point-of-care
applications.
In
this
context,
direct
infusion
(DI)
ambient
ionization
(AI)
MS,
where
samples
can
be
analysed
directly,
rapidly,
minimal
handling,
offer
attractive
alternatives
hyphenated
methods.
Recent
technological
advances
have
addressed
the
typical
issues
of
AIMS
DIMS
methods
regarding
metabolome
coverage,
reproducibility,
repeatability
encountered
during
their
early
development.
systematic
review,
we
discussed
recent
(2017–2023)
original
publications
on
DIMS-
AIMS-based
biofluid
considering
reported
biomedical
implementations,
assets
workflow,
data
handling
coherence
platforms.
Biomedical Chromatography,
Journal Year:
2025,
Volume and Issue:
39(5)
Published: April 7, 2025
ABSTRACT
Shenhua
tablets
(SHT),
a
traditional
Chinese
medicine
(TCM),
have
shown
significant
clinical
efficacy
in
treating
IgA
nephropathy
(IgAN),
but
the
underlying
mechanisms
are
not
fully
understood.
This
study
aims
to
elucidate
renoprotective
effects
of
SHT
on
IgAN
and
explore
potential
its
action
using
metabolomics
approaches.
The
were
evaluated
Thy‐1
antibody‐induced
rat
model.
Metabolomics
techniques
employed
detect
analyze
urine
biomarkers
IgAN,
identify
targets
metabolic
pathways.
significantly
reduced
levels
24‐h
protein
(Upro),
albumin‐to‐creatinine
ratio
(ACR),
Interleukin
1β
(IL‐1β),
tumor
necrosis
factor‐α
(TNF‐α),
interleukin
6
(IL‐6),
alleviated
kidney
tissue
damage,
inhibited
mesangial
cell
proliferation.
Seventeen
metabolites
identified
as
for
14
which
restored
by
SHT.
primarily
modulated
pathways,
including
tricarboxylic
acid
(TCA)
cycle,
glycolysis/gluconeogenesis,
pyruvate
metabolism,
β‐alanine
upregulating
citric
succinic
while
downregulating
pyruvic
acid,
L‐lactic
uracil,
malonic
semialdehyde.
exerts
modulating
key
pathways
normalizing
abnormal
levels.
